Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Cash from Financing Activities (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Cash from Financing Activities for 8 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 55.56% to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $23.6 million, a 50.24% decrease, with the full-year FY2024 number at $50.4 million, up 836.51% from a year prior.
  • Cash from Financing Activities was $1.7 million for Q3 2025 at Precision Biosciences, down from $5.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $92.9 million in Q2 2022 to a low of -$180000.0 in Q3 2022.
  • A 5-year average of $13.3 million and a median of $4.5 million in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 11592.68% in 2021, then crashed 101.51% in 2022.
  • Precision Biosciences' Cash from Financing Activities stood at $8.4 million in 2021, then tumbled by 102.15% to -$180000.0 in 2022, then skyrocketed by 1671.11% to $2.8 million in 2023, then skyrocketed by 109.34% to $5.9 million in 2024, then tumbled by 71.98% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Cash from Financing Activities are $1.7 million (Q3 2025), $5.3 million (Q2 2025), and $10.7 million (Q1 2025).